

Georg Thieme Verlag  
**Scientific articles**  
Authors' Guidelines



## Publishing scientific articles with Thieme

We are pleased that you intend to publish an **original contribution**, **review article** or **scientific case report** in a Thieme journal! The formal requirements your manuscript should meet are explained below.

**Please note: We only accept manuscripts that have not yet been published or submitted elsewhere.** If the content of your article has already been presented orally at a conference, please note this with reference to the type, place, and date of the meeting.

### Figures: rights of use / copyright / personal rights

Unfortunately, we cannot accept **images that have already been published in books, journals, or electronic products of other publishers**. That is because it is almost impossible to obtain the necessary rights of use even when licensing fees are paid. Therefore, **please do not pay any licensing fees** (e.g. to "RightsLink" / Copyright Clearance Center). Standard license contracts from "Creative Commons" are unfortunately also insufficient for our purposes. Please contact us if you have any questions regarding the use of images.

The **personal rights** of people who are recognizable on images must be protected. Please provide a **written consent form** for publication signed by every recognizable person. For persons under 18 years of age / persons supervised, please provide the signature of both parents / the legal guardian / supervisor. A suitable declaration of consent form can be obtained in our [authors' lounge](#).

We cannot accept or store illustrations in which **personal data of third parties** are included. Please submit images in completely anonymous form, **free of personal data** only!

Such data may not only be directly visible in the image (e.g., a patient name or a date of birth in an X-ray image); they can also be included in the metadata of the image, which is accessible with the appropriate software. They may also be obscured by a cropping feature (such as Powerpoint or Word), but can be made visible underneath. If you have questions about data protection regulations, please contact us before submitting your manuscript.

### File format und general requirements

Please submit your material in the following form:

- **Text and tables:** MS Word (\*.doc, \*.docx)
- **Figures:** each figure as separate image file (\*.jpg, \*.tif, \*.png), for drawings and graphics also MS Word or Powerpoint. Minimum resolution: 300 dpi at 8,5 cm width (1000 pixel width)
- **Videos:** preferred file format \*.mp4, \*.avi or \*.mov, file size max. 5 MB per video
- **Audio files:** preferred file format \*.wav
- For structuring the main text, you may use **up to 3 levels of headings** (in decimal numeration). Please do not use frames, text boxes, coloured or italicized text.
- The text may contain **enumerations** in max. 3 levels.
- Please add **references to literature, tables, and figures** (see below).

### Scientific vocabulary

- Please use SI units for **laboratory data**.
- Please use only **abbreviations** that are generally known and explain necessary abbreviations where they are introduced. Please avoid abbreviations in the title of the manuscript.

- In case of **drugs and pharmaceutical products**, please use the international nonproprietary name (INN, generic name).
- For **medical devices/machines**, please mention the product name/trademark, manufacturer and country of origin (in brackets).
- **Trademarks** of registered preparations, processes, substances, devices etc. should be labeled with <sup>®</sup>, <sup>™</sup> or <sup>SM</sup> **not more than once** in the article (e.g. ATLS<sup>®</sup>). At later occasions, the symbol is to be omitted (e.g. ATLS). Ideally, the symbol is used at the **first** mentioning of the trademark (but **not in the title of the article**). The symbols <sup>®</sup>, <sup>™</sup> or <sup>SM</sup> must be used **equally for all trademarks** mentioned in the article. An inconsistent use, where only part of the registered trademarks are identified, must be avoided for adequate trademark protection.

## Code names / fake names / fictional personal data

According to Thieme guidelines, data about actual persons must be systematically alienated to protect personal rights and to make code names always recognizable as such.

If one or several persons are provided with code names in pictures or texts, the following options are to be used:

- **Individual persons** (for example individual persons on forms / exemplary filled in prescriptions / templates):
  - male: Herr M., M. Mustermann, Max Mustermann
  - female: Frau M., E. Musterfrau, Erika Musterfrau
- **Several persons** (for example exemplary tables / charts / surveys / complex case examples):
  - male: Alexander, Alfred, Felix, Johannes, Julius, Karl, Leon, Ludwig, Niklas, Samuel
  - female: Anna, Charlotte, Clara, Emma, Frieda, Johanna, Laura, Lena, Mia, Sophie
- Use of surnames: **As standard, only abbreviated surnames are used.** Valid abbreviations are: B., D., L., M., N., P., R., S., T. If absolutely necessary in an individual case, the following written-out German surnames are also valid: Bauer, Müller, Meyer, Schneider, Fischer.
- **Individual persons** (English):
  - male: Mr. D., J. Doe, Jon Doe
  - female: Ms. D., J. Doe, Jane Doe
- **Several persons** (English):
  - male: Andrew, Charles, David, George, James, Michael, Matthew, Robert, Thomas, William
  - female: Anne, Bridget, Catherine, Emily, Elizabeth, Jane, Melissa, Sarah, Susan, Victoria
- If absolutely necessary in an individual case, the following written-out English surnames are also valid: Brown, Jones, Smith, Taylor, Williams.
- If **names from further language areas** are required (for example Turkish, Russian, Spanish names), they must be unambiguously labeled as editorially changed names in the text as well as in the caption of figures (for example within a footnote or with the phrase “editorially changed names“ in parentheses).
- Further fictional data is combined with the word “Muster” or the word “sample” in English (for example Musterfirma, Musterinstitut, Sample Company, Sample Institute). Furthermore, the following applies:
  - addresses: Musterstraße 123, 1234 Musterstadt
  - date of birth without numbers: TT.MM.JJJJ
  - phone number: (01234) 56789-0
  - medication: Mustermedikament
  - result: Musterbefund

## Structure of your article

### Title

- Please do not mention any product / company names or trademarks in the title.

### Authors

- Names of **all authors** (complete **first and last names**). For authors who have an [ORCID](#) ID, please add this. For online submissions, please enter this information only in the appropriate fields.
- If the authors come from different **institutions**, please indicate their affiliation with the following institutions by indices. If available, please also specify the [Ringgold Identifier](#) for each institution.
- After acceptance of the manuscript, the authors' order (first author, last author, etc.) can be changed only with the consent of all authors.
- **Acknowledgements** to colleagues whose contribution does not justify a citation as a co-author, or credits for financial or other support, should be put at the end of the manuscript.

### Abstract and keywords

- Please do not use abbreviations or references to figure, tables or literature in the abstract.
- For online submissions, please enter the abstract in the appropriate field.
- Please provide **3–5 key words**.

### Figures

- Accepted file formats and minimum resolution: see above
- Please provide a concise, complete **legend** for each figure, including diagnosis, examination methods, clinical findings and explanation of abbreviations. It should be as complete as possible, so that the figure can be adequately registered in databases.
- please add **references** to each figure: (figure 1) etc. In the text at the appropriate place,
- The **total number of characters** that your manuscript should contain is reduced by each figure that will be printed in your article:
  - for “regular“ figures (ca. ¼ print page) by about 1000 characters (including spaces)
  - for larger figures, e.g. algorithms (ca. ½ print page) by about 2000 characters (including spaces)

### Tables

- Tables should have **2 columns or more**. Tables of 1 column should be set as an enumeration in the main text.
- **Number** the tables consecutively and add the **reference** at the appropriate place in the text.
- Please provide a **caption** for each table, e.g.: “Tab. 1: Differential diagnosis of acute chest pain”. Additionally, please provide a heading for each column or for the whole table.
- Tables may have **subheadings** within – please identify them e.g. in **bold** letters and take care to connect the cells as adequate.

Example:

Tab. 1: Caption

	<b>Heading column 1</b>	<b>Heading column 2</b>
Text	Text	Text
Text	Text	Text
<b>Subheading</b>		

Text	Text	Text
Text	<ul style="list-style-type: none"> <li>• enumeration</li> <li>• enumeration</li> </ul>	Text

## Bibliography

References are to be **numbered** (e.g. [9]) in the main text. The bibliography must list **all references** mentioned in the text. They are sorted in the order in which they occur in the text (not in alphabetical order).

- ➔ If you are working with a **citation management software** (Endnote, Zotero, Mendeley), please use the **Output Style “Thieme-German”**. It is available in the respective software or simply download it in our [authors' lounge](#).
- ➔ **doi** (digital object identifier): The doi is an unambiguous and permanent digital identifier. It is mainly used for electronically published scientific articles, but increasingly also for books and book chapters. **If the doi is available, please add it in the recommended notation (see below).**
- **Journal articles** should be cited as follows (after 3 authors „et al“):  
 [1] Schnoor J, Gillmann B, Pavlakovic G et al. Characteristics of repeated emergency physician use. Phys Med 2006; 22: 141–146  
**with doi:** Schnoor J, Gillmann B, Pavlakovic G et al. Characteristics of repeated emergency physician use. Phys Med 2006; 22: 141–146. doi:10.1055/s-0041-118769
- **Online / eFirst / ePub ahead of print articles** should be cited as follows:  
 [2] Schnoor J, Gillmann B, Pavlakovic G et al. Characteristics of repeated emergency physician use. Phys Med 2006. doi:10.1055/s-0042-117551
- **Books** should be cited as follows (please list all authors / editors):  
 [3] Eisen HN, Sproch C. Immunology: an Introduction to molecular and cellular Principles of the immune Response. 5th ed. New York: Harper and Row; 1974  
 [4] Eisen HN, Sproch C, eds. Immunology: an Introduction to molecular and cellular Principles of the immune Response. 5th ed. New York: Harper and Row; 1974
- **Book chapters** should be cited as follows:  
 [5] Weinstein L, Swartz MN. Pathogenic Properties of invading Microorganisms. In: Sodeman WA jr., Sodeman WA, eds. Pathologic Physiology: Mechanisms of Disease. Philadelphia: WB Saunders; 1974: 457–472
- **Online literature** should be cited as follows:  
 [6] Lund University Hospital. Door to balloon-times for patients with acute cardiac infarction (December 2016). Online: [www.lunduniversity.lu.se/article/door-to-balloon-times](http://www.lunduniversity.lu.se/article/door-to-balloon-times); last accessed: 21.11.2017
- **Unpublished findings or personal communications** are not listed in the bibliography, but mentioned in the main text. Personal communications may only be cited with the written consent of the person mentioned.
- **Congress abstracts / congress communications** may be cited if they have been published as abstract or as chapter in a “proceedings” volume.

## Statistics

- Your article should conform to the relevant **reporting guidelines** (see [Equator Network](#)). For randomized controlled trials, this is e.g. the [CONSORT 2010 Statement](#).
- For all numerical data (e.g. number of patients, trials, etc.), please specify not only the relative frequencies (percentages), but also the basic **total observation number**.
- For statistics (especially significance tests), please clearly indicate the **statistical method** used and the numerical result of the **computed test statistic** (e.g. for t-tests, chi-square-test, F-test, etc.). Where appropriate, please explain which **significance level** you consider appropriate to the medical problem (typically 5%, 1% or 0.1%).
- When describing oncological patients, please apply a classification according to the **TNM system** (current edition).

## Ethical aspects

Please clarify whether your study requires the advice or approval of an ethics committee and / or a government authority. For more information, see the [Declaration of Helsinki](#) and the [International Committee of Medical Journal Editors](#) (ICMJE).

- For all studies involving persons, the author must, if applicable, have a positive vote of the relevant regional or institutional **ethics committee** and / or a **government authority**. In the absence of a vote, such as in the case of retrospective studies, this shall be explained in a statement to the editor. In such cases, the corresponding author must confirm compliance with the current version of the [Declaration of Helsinki](#). Both are to be specified in the “Methods” part of the article.
- For clinical trials, please add the **Clinical Trial Registration Number** (e.g. [ClinicalTrials.gov](#) or [ISRCTN Registry](#)) in the manuscript.
- Patient names, initials or file numbers may only be used with the written permission of the patient (please pay attention to illustrations). You can obtain the corresponding form from your contact person in our publishing house or online in our [authors' lounge](#).
- In experiments with animals, all applicable provisions of **animal welfare** must be observed. This must be confirmed in the “Methods” part of the article.

## Financial support

Please indicate in the manuscript whether (and if so: by whom) the study or publication was financially supported (above of the conflict of interest). If the supporting institution is listed in the database [Crossref](#), please use the name as it is mentioned there (you can open the file with a text editor, an Internet browser or MS Word).

## Conflict of interest

Please indicate a possible [conflict of interest](#) (COI) in your manuscript, and insert it **above the bibliography**. You will additionally receive our COI form together with the galley proof (see below) in order to add / check this information.

## Legal aspects

- **Manuscripts that have already been published or submitted elsewhere are not to be submitted and will not be accepted for publication.**
- The **corresponding author** has to make sure that the remaining authors agree with the publication of the article in the version presented.
- With the acceptance of the manuscript, the publisher acquires **rights of use** for the duration of the legal protection period.
- The **moral rights** of the manuscript remain with the authors.
- The publication may not infringe the **rights of third parties**.
- For details, please refer to the [CTA form](#) (Copyright Transfer Agreement) in our [authors' lounge](#).

## Open Access

Thieme offers Open Access publications in fully Open Access journals, as well as articles published on an Open Access basis in our subscription journals. For detailed information on different possibilities and article publication charges, please visit our [Thieme Open Website](#). Charges are determined by the date the manuscript is accepted for publication.

## Submitting your manuscript

For detailed information on how to submit your paper, please refer to the **website of the respective journal**. It will provide additional information on individual sections and types of articles as well as the editorial office. An alphabetical **list of all our journals** with links to the corresponding websites can be found [on our website](#).

## Peer review of your manuscript

- After submission, your manuscript will be **peer reviewed**. If the reviewers have any questions or comments, the corresponding author will be informed.
- If a revision / correction of the manuscript is recommended, please mark / highlight **any changes** you make in the text. Answer to the reviewers' comments item by item, e.g. in an accompanying letter. When submitting online, you will be offered an input mask for this purpose.

## Author's proofs and approval

The **corresponding author** will receive the galley proofs as a PDF file, together with a **copyright transfer agreement** (CTA) and a declaration of **conflicts of interest** (COI).

The author(s) should

- **carefully check** the galley proofs (especially numbers, units, dosages, etc.) and
- **mark final corrections**, if necessary (use only the tools offered by PDF files).
- Finally, you return the corrected PDF, together with the digitally signed CTA and COI forms.
- Please note: After the manuscript is accepted for publication by the reviewers, **only formal corrections are possible** – the content of the article must not be changed.

The timely return is a precondition for timely publication. The costs for exceptionally large or belatedly returned corrections can be billed by the publisher. The corresponding author is fully responsible for the correctness of the final version that he / she accepts and releases for publication. **After sending in the copyright transfer agreement, changes by the authors are no longer possible.** The date when the publisher provides the galley proofs does not allow conclusions as to the publication date of the article.

### **Electronic reprint for personal use**

After publication, the corresponding author receives a free **electronic reprint** (PDF file). Authors may use it for the professional exchange with colleagues and are free to upload the file on their personal homepage. Please note that all further use of this PDF is subject to approval by the publisher. Especially any commercial use or deposition of the file in repositories (e.g. document servers of libraries and other institutions) is prohibited.

**Thank you very much for your cooperation!**



Georg Thieme Verlag KG  
Rüdigerstraße 14 • 70469 Stuttgart  
Telefon: +49 711 8931-0  
Fax: +49 711 8931-298

